The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	15.15B
Revenue (ttm)	33.50B
Net Income (ttm)	2.39B
Shares Out	211.60M
EPS (ttm)	11.30
PE Ratio	6.34
Forward PE	n/a
Dividend	3.50 (4.88%)
Ex-Dividend Date	Nov 21, 2024

Volume	61,114
Average Volume	79,085
Open	71.90
Previous Close	71.70
Day's Range	71.00 - 71.90
52-Week Range	62.60 - 94.50
Beta	0.10
RSI	41.35
Earnings Date	Apr 24, 2025

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacture, market, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and stero...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,301
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2024, The ACME Laboratories's revenue was 31.93 billion, an increase of 18.49% compared to the previous year's 26.95 billion. Earnings were 2.46 billion, an increase of 6.62%.